The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and -resistant enterococci

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 971-974

  Miyazaki, Shuichi ^a   Fujikawa, Toshihiko ^a   Kobayashi, Intetsu ^a   Matsumoto, Tetsuya ^a   Tateda, Kazuhiro ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Linezolid; Vancomycin; VRE; VSEF

Indexed keywords

CYCLOPHOSPHAMIDE; DALFOPRISTIN PLUS QUINUPRISTIN; KANAMYCIN; LINEZOLID; METRONIDAZOLE; MINOCYCLINE; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; IN VIVO STUDY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; ENTEROCOCCUS FAECALIS; HUMANS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0036920076     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf245     Document Type: Article

References (16)

1. Lucas, G. M., Lechtzin, N., Puryear, D. W., Yau, L. L., Flexner, C. W. & Moore, R. D. (1998). Vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia: comparison of clinical features and outcomes. Clinical Infectious Diseases 26, 1127-33.
2. Schulin, T., Thauvin-Eliopoulos, C., Moellering, R. C., Jr & Eliopoulos, G. M. (1999). Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 43, 2873-6.
3. Patel, R., Rouse, M. S., Piper, K. E. & Steckelberg, J. M. (2001). Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrobial Agents and Chemotherapy 45, 621-3.
4. Montecalvo, M. A., Horowitz, H., Gedris, C., Carbonaro, C., Tenover, F. C., Issah, A. et al. (1994). Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteraemia in an adult oncology unit. Antimicrobial Agents and Chemotherapy 38, 1363-7.
5. Edmond, M. B., Ober, J. F., Weinbaum, D. L., Pfaller, M. A., Hwang, T., Sanford, M. D. et al. (1995). Vancomycin-resistant Enterococcus faecium bacteraemia: risk factors for infection. Clinical Infectious Diseases 20, 1126-33.
6. Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, P. R. & Wenzel, R. P. (1999). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clinical Infectious Diseases 29, 239-44.
7. Miyazaki, S., Fujikawa, T., Kobayashi, I., Matsumoto, T., Tateda, K. & Yamaguchi, K. (2001). Development of systemic bacteraemia after oral inoculation of vancomycin-resistant enterococci in mice. Journal of Medical Microbiology 50, 697-701.
8. Sahm, D. F., Kissinger, J., Gilmore, M. S., Murray, P. R., Mulder, R., Solliday, J. et al. (1989). In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrobial Agents and Chemotherapy 33, 1588-91.
9. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA.
10. Wise, R., Andrews, J. M., Boswell, F. J. & Ashby, J. P. (1998). The in-vitro activity of linezolid (U-100766) and tentative break-points. Journal of Antimicrobial Chemotherapy 43, 466-8.
11. Garbutt, J. M., Ventrapragada, M., Littenberg, B. & Mundy, L. M. (2000). Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteraemia. Clinical Infectious Diseases 30, 466-72.
12. Pelton, S. I., Figueira, M., Albut, R. & Stalker, D. (2000). Efficacy of linezolid in experimental otitis media. Antimicrobial Agents and Chemotherapy 44, 654-7.
13. Dailey, C. F., Dileto-Fang, C. L., Buchanan, L. V., Oramas-Shirey, M. P., Batts, D. H., Ford, C. W. et al. (2001). Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 45, 2304-8.
14. Rybak, M. J., Hershberger, E., Moldovan, T. & Grucz, R. G. (2000). In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrobial Agents and Chemotherapy 44, 1062-6.
15. Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K. & Quinn, J. P. (2001). Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179.
16. Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L. et al. (2001). Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-8.